<div>
  <ul>
    <li>
      <p>
        Climeworks, a Swiss direct air capture (DAC) startup, has signed a carbon dioxide (CO2) removal agreement with Ocado Retail, the world's largest dedicated online supermarket.
      </p>
    </li>
  </ul>
  <ul>
    <li>
      <p>
        Climeworks will capture CO2 from the atmosphere via its proprietary direct air capture and storage technology.
      </p>
    </li>
  </ul>
  <ul>
    <li>
      <p>
        Ocado Retail has agreed to purchase 1,000 tons of CO2 from Climeworks, which would be equivalent to CO2 emitted from Ocado Retail&rsquo;s head office over seven years.
      </p>
    </li>
  </ul>
  <ul>
    <li>
      <p>
        The partnership is in line with Ocado Retail&rsquo;s goal to become net-zero by 2040 and would reportedly make Ocado Retail the world&rsquo;s first supermarket to operate a carbon-free head office.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://climeworks.com/news/ocado-retail-purchases-climeworks-carbon-dioxide-removal">
      Press release
    </a>
  </p>
  <p>
    <a href="https://www.thegrocer.co.uk/ocado/ocado-retail-claims-world-grocerys-first-net-zero-head-office/661958.article">
      The Grocer
    </a>
  </p>
</div>


Alternative Energy

Climeworks signs deal to capture carbon emission for Ocado Retail

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

<div>
 <p>ABVC BioPharma's subsidiary, AiBtl BioPharma, has acquired precision medicine manufacturer TT Life Company. The deal involved the purchase of 1.66 million shares at USD 5.00 per share, putting the deal's value at around USD 8.33 million. Other acquisitions included a Malaysian import trading company and a Taiwanese direct sales company.</p>
 <p>Taking advantage of TT Life Company's expertise in product design and manufacturing, the acquisition is expected to create synergies across research &amp; development, manufacturing, distribution, and financial capabilities. This could allow AiBtl to introduce a broad range of AI-driven precision medicines.</p>
 <p>As a biopharmaceutical company, AiBtl BioPharma focuses on the development of innovative therapies for central nervous system disorders such as major depressive disorder (MDD) and ADHD. Their approach involves the use of plant-based norepinephrine transporter inhibitors, currently in clinical trials. One drug is in Phase IIb trials, while another has finished Phase II and is moving towards Phase III. While the company operates from the United States, it has substantial activities in Asia, with clinical trials conducted in Cambodia, Thailand, and Japan.</p>
</div>

AiBtl BioPharma acquires TT Life Company to broaden precision product portfolio

<div>
 <p>Diamyd Medical has recently concluded its company rights issue which ended on April 16, 2024. Several key individuals including the founder and chairman of the board, Bertil Lindkvist, who is also the company’s principal shareholder, as well as other top-ranking executives and board members were among the subscribers in the issue.</p>
 <p>The Rights Issue consists of 9,494,799 units, with 4,216,203 units being subscribed for with unit rights, making up approximately 44% of the complete issue. Subscriptions for 558,779 units have been received without unit rights, which represent roughly 6% of the total units offered. The company has announced that it expects the final proceeds from the Rights Issue to be around SEK 57 million, or approximately USD 5.2 million once costs have been deducted, however it has not yet announced the intended use for these funds.</p>
 <p>As part of their ongoing strategy, Diamyd Medical has stated that they plan to persist in their current line of work, particularly following the recent <a href="https://www.diamyd.com/docs/pressClips.aspx?ClipID=4751158#:~:text=About%20Diamyd%20Medical&amp;text=Diamyd%C2%AE%20is%20an%20antigen,designation%20by%20the%20U.S.%20FDA."> receipt of FDA Fast Track designation for their Diamyd therapy product (rhGAD65/alum) </a> , which is being developed to improve glycemic control in those with Stage 3 type 1 Diabetes who possess the genotype HLA DR3-DQ2.</p>
 <p>Diamyd Medical is a company rooted in Sweden that is known for its specialty in developing precision medicine therapies for autoimmune diabetes, including type 1 Diabetes and Latent Autoimmune Diabetes in Adults (LADA). The companies innovative approach to preserving naturally occurring insulin production through their leading product, Diamyd, which is an antigen-specific immunotherapy, sets it apart within its field.</p>
</div>

Diamyd Medical secures ~USD 5.2 million in rights issue

PROMINENT_CATEGORY

<div>
 <p>Genetic Technologies has entered an agreement to sell 1,000,000 American Depositary Shares (ADSs) at USD 2.00 each, along with unregistered warrants to purchase up to 1 million ADSs in a private placement. The gross proceeds are expected to be around USD 2 million.</p>
 <p>The proceeds will help in the commercialization of the GeneType Multi Risk test, support digital strategy, expansion into European and Southeast Asian markets, launch its Comprehensive Hereditary Breast and Ovarian Cancer Risk Test, and other corporate purposes.&nbsp;</p>
 <p>The company has also established a precision oncology division to aid in effective cancer therapy selection. The diagnostic tests feature methylation tests developed in collaboration with the University of Melbourne Department of Surgery, solid tumor mutation, and liquid biopsy tests.</p>
 <p>Genetic Technologies is based in Australia and specializes in predictive genetic testing and risk assessment tools. The company offers tests like BREVAGenplus for non-hereditary breast cancer and GeneType for various cancers including colorectal, ovarian, and prostate.</p>
</div>

Genetic Technologies raises USD 2 million in direct offering to fund product and market development

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 <p>Cognivia, a company specializing in creating AI-based predictive analytical tools, has successfully raised 15.5 million Euros (about 16.5 million USD) in a funding round. Key investors included Vesalius Biocapital IV, SFPIM, and Wallonie Entreprendre. </p>
 <p>These funds will be used to increase the global reach of Cognivia's predictive clinical trial solutions, especially in the United States. The company plans to expand its team and establish a US subsidiary to support commercial and R&D partnerships.&nbsp;</p>
 <p>Previously known as Tools4Patient, Cognivia is a private firm located in Belgium. The company creates AI tools intended to improve and speed up drug development. Placebell and Compl-AI are some of the products that Cognivia offers, which aim to predict placebo responsiveness and ensure patient compliance in clinical trials.</p> 
</div>

Cognivia raises Euro 15.5 million in strategic funding to enhance AI/ML drug development

AI-based solutions for evolving digital threats

Next-gen Cybersecurity

INCUMBENTS_PRESENT

<div>
 
 <p>Mulberri, an AI-powered insurance platform, has teamed up with Acronis, a cyber security company, to offer cyber insurance to small and medium-sized enterprises (SMEs). The insurance will be provided through the Acronis platform.</p>
 <p>Thanks to this partnership, Mulberri and Acronis can provide comprehensive solutions to Acronis clients to protect against the risk of cyber threats.</p>
 
</div>

Mulberri partners with Acronis to provide embedded cyber insurance for US-based SMBs

New data privacy regulations have opened up space for a new wave of compliance-focused startups.

Digital Privacy Tools

<div>
 
 <p>Mulberri and Acronis have partnered to offer cyber insurance to small and medium businesses (SMBs). This partnership extends end-to-end solutions for Acronis customers against cyber threats.</p>

</div>

Helping employers provide personalized, high-touch, and holistic financial wellness tools to their entire workforce.

Financial Wellness Tools

ANALYST_QUICK_TAKE

<div>
 
 <p>Marqeta, a card issuing infrastructure provider, is partnering with financial wellness platform Rain to launch the Rain Card, a branded debit card for employers to access earned wages.</p>
 <p>Rain will use Marqeta’s card issuing abilities to create a debit card aimed at reducing dependency on credit and promoting better financial management. This collaboration also provides Marqeta with an expanded product reach and growth in transaction processing volumes.</p>
 <p>Rain's customer base includes global brands like Hilton, McDonald’s, Arby’s, and Subway, and spans various industries including restaurants and hospitality, healthcare, and retail.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> Marqeta also launched a <a href="https:<br>
//sp-edge.com/updates/23011"> credit card-issuing platform </a> supporting consumer and commercial credit programs in October last year. This partnership follows nearly two months after <a href="https:<br>
//sp-edge.com/companies/999264"> Rain </a> secured USD 300 million via a <a href="https:<br>
//sp-edge.com/updates/27208"> credit facility </a> to expand product offerings, which also marks the highest amount in funding raised for the year by a disruptor in the financial wellness space.</p>

Marqeta announces partnership with Rain to launch Rain Card

Democratizing financial technology with a suite of API-based solutions

FinTech Infrastructure

<div>
 
 <p>Card issuing infrastructure provider, Marqeta, has teamed up with Rain, a financial support and wellness platform for employers. They are launching the Rain Card, a branded debit card that enables employers to access earned wages instantly.</p>
 <p>With this partnership, Rain aims to utilize Marqeta's card issuing abilities to launch a branded debit card. This debit card offers users access to their earned wages, encouraging less reliance on credit and better financial management. Marqeta, on the other hand, enjoys broader product reach and increased transaction processing volumes due to this collaboration.</p>
 <p>Among Rain's current clientele are global brands such as Hilton, McDonald’s, Arby’s, and Subway, spanning various industries like restaurants and hospitality, healthcare, and retail.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> Marqeta also launched a <a href="https:<br>
//sp-edge.com/updates/23011"> credit card-issuing platform </a> supporting consumer and commercial credit programs in October last year. This partnership follows nearly two months after <a href="https:<br>
//sp-edge.com/companies/999264"> Rain </a> secured USD 300 million via a <a href="https:<br>
//sp-edge.com/updates/27208"> credit facility </a> to expand product offerings, which also marks the highest amount in funding raised for the year by a disruptor in the financial wellness space.</p>

Clean, congestion-free air travel gets liftoff

Passenger eVTOL Aircraft

<div>

 <p>UK-based aerospace technology firm, Evolito Ltd, has hired Marcus Holme as its new CTO. Holme, who has a Master's degree in power electronics and 24 years of aviation experience, will lead the technology development and focus on the axial-flux e-motor and propulsion product family of Evolito. He previously served as senior director of engineering at Collins Aerospace, where he dealt with multiple aircraft system electrification programs.&nbsp;</p>
 <p>Evolito, a company established in 2021, specializes in axial-flux electric motors, power electronics, and battery solutions for aerospace applications. In December 2023, Evolito received the UK Civil Aviation Authority's Design Organisation Approval (DOA) for its electric propulsion system products. The firm partners with numerous OEMs to create motors and propulsion systems for eVTOL, urban air mobility, and fixed-wing applications.</p>

</div>

Evolito appoints Marcus Holme as CTO to transform air travel

Technology to explore opportunities beyond Earth

Space Travel and Exploration Tech

<div>
 
 <p>Orbex, a space launch firm based in the UK, has secured around USD 20.77 million financing in a round led by SNIB, Octopus Ventures, BGF, and Heartcore, as well as EIFO and several corporate and individual investors. The raised funds will be used to further progress the development of Orbex's small satellite launch rocket. After testing and commencing launches, Orbex aims to initiate a Series D funding round to ensure long-term sustainability.</p>
 
</div>

All Updates

AiBtl BioPharma acquires TT Life Company to broaden precision product portfolio

Diamyd Medical secures ~USD 5.2 million in rights issue

Genetic Technologies raises USD 2 million in direct offering to fund product and market development

Cognivia raises Euro 15.5 million in strategic funding to enhance AI/ML drug development

Mulberri partners with Acronis to provide embedded cyber insurance for US-based SMBs

Mulberri partners with Acronis to provide embedded cyber insurance for US-based SMBs

Marqeta announces partnership with Rain to launch Rain Card

Marqeta announces partnership with Rain to launch Rain Card

Evolito appoints Marcus Holme as CTO to transform air travel

Orbex raises GBP 16.7 million to advance development of rocket